The Oxford/AstraZeneca COVID-19 vaccine, given in two doses, is 92% effective against hospitalizations by the so-called Delta variant. According to the Oswaldo Cruz Foundation (Fiocruz), AstraZeneca’s partner in Brazil, the data is part of a pre-print study by the British government health agency PHE, published on June 14th. With just one dose, the effectiveness of the Oxford/AstraZeneca vaccine against hospitalizations for the Indian variant is 71%.
The survey, which in addition to the Oxford/AstraZeneca vaccine also researched the effects of the Pfizer vaccine, includes data from 14,019 cases of the Delta variant, which arrived at emergency rooms in English hospitals between April 12 and June 4 this year. Of these, 166 patients needed to be hospitalized. None of them died.